comparemela.com

Latest Breaking News On - Corvus pharmaceuticals trading down - Page 1 : comparemela.com

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

William Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William-benton-jones
Cantor-fitzgerald
Exchange-commission
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-trading-down
Institutional-trading-of-corvus-pharmaceuticals
Corvus-pharmaceuticals-inc
Nasdaq
Corvus-pharmaceuticals
Securities-exchange-commission
Get-free-report
Pharmaceuticals-trading-down

Towerview LLC Has $500,000 Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Towerview LLC Has $500,000 Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Quarter-for-corvus-pharmaceuticals
Tucker-asset-management
Corvus-pharmaceuticals-trading-down
Corvus-pharmaceuticals
Renaissance-technologies
Virtu-financial
Nasdaq
Tower-research-capital
Corvus-pharmaceuticals-inc
News-ratings-for-corvus-pharmaceuticals-daily
Exchange-commission

Towerview LLC Has $500,000 Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Towerview LLC Has $500,000 Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

York-mellon-corp
Virtu-financial
Charles-schwab-investment-management-inc
Corvus-pharmaceuticals-inc
News-ratings-for-corvus-pharmaceuticals-daily
Tucker-asset-management
Corvus-pharmaceuticals
Tower-research-capital
Nasdaq
Corvus-pharmaceuticals-trading-down
Quarter-for-corvus-pharmaceuticals

Corvus Pharmaceuticals (NASDAQ:CRVS) Given "Overweight" Rating at Cantor Fitzgerald

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $4.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 148.45% from the company’s previous close. […]

Virtu-financial
Cantor-fitzgerald
Nasdaq
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals-trading-down
Institutional-trading-of-corvus-pharmaceuticals
Renaissance-technologies
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals
Corvus-pharmaceuticals-inc
Charles-schwab-investment-management-inc

Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $12.00 Price Target at LADENBURG THALM/SH SH

Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) had its price objective boosted by LADENBURG THALM/SH SH from $10.00 to $12.00 in a report issued on Monday, FlyOnTheWall reports. CRVS has been the topic of a number of other reports. StockNews.com began coverage on shares of Corvus Pharmaceuticals in a report on Thursday, May 18th. They set […]

Vanguard-group-inc
Corvus-pharmaceuticals-trading-down
Cantor-fitzgerald
Morgan-stanley
Acadian-asset-management
Renaissance-technologies
Corvus-pharmaceuticals-company-profile
News-ratings-for-corvus-pharmaceuticals-daily
Institutional-investors-weigh-in-on-corvus-pharmaceuticals
Corvus-pharmaceuticals
Corvus-pharmaceuticals-inc

vimarsana © 2020. All Rights Reserved.